rs2249891 — ABCA1

ABCA1 — The HDL Formation Rate-Limiter

Your body cannot manufacture high-density lipoprotein particles from scratch — it has to build them one lipid at a time. The key enzyme driving that process is ABCA1¹¹ ABCA1
ATP-binding cassette transporter A1, a membrane protein that pumps cholesterol and phospholipids out of cells onto apolipoprotein A-I scaffolds. rs2249891 sits in the fourth intron of the ABCA1 gene and is one of several common variants at this locus that have been linked to variation in HDL-C levels. ABCA1 is among the most replicated lipid GWAS loci in human genetics.

The Mechanism

ABCA1 catalyzes the rate-controlling step in reverse cholesterol transport²² reverse cholesterol transport
the pathway by which peripheral tissues off-load excess cholesterol back to the liver for excretion — the transfer of cellular cholesterol and phospholipids to lipid-poor apolipoprotein A-I (apoA-I). This lipidation event creates nascent HDL particles, which mature as they circulate and pick up additional lipids from other transporters (ABCG1, SR-BI). The rs2249891 variant is intronic (c.422-161T>C on the coding strand, which corresponds to A>G on the genomic plus strand) and does not alter the ABCA1 protein directly. It likely acts as a tag for functional regulatory variation nearby, or contributes through subtle effects on splicing efficiency or transcriptional regulation that reduce ABCA1 expression in relevant tissues such as the liver and macrophages.

When ABCA1 activity is reduced — whether by coding mutations (Tangier disease) or by common regulatory variants — cholesterol efflux from macrophages in arterial walls is impaired. Lipid-laden macrophages become foam cells, the building blocks of atherosclerotic plaques.

The Evidence

The ABCA1 locus has been implicated in HDL-C levels since early GWAS work. Willer et al.³³ Willer et al.
Willer CJ et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet, 2008 confirmed ABCA1 among eleven established lipid loci in a genome-wide scan of ~20,000 individuals. The specific variant rs2249891 was identified by Peloso et al.⁴⁴ Peloso et al.
Peloso GM et al. Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. J Lipid Res, 2010 in a candidate-gene study of 60 key HDL-metabolism genes across 699 cases (low HDL-C plus coronary heart disease, from the VA-HIT trial) and 705 controls (Framingham Offspring Study). The G allele showed significant association with case status after adjustment for multiple testing within the gene (P = 0.0126).

Importantly, a comprehensive review⁵⁵ comprehensive review
Frikke-Schmidt R. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease. Atherosclerosis, 2010 established that both common and rare ABCA1 variants contribute to HDL-C levels and ischemic heart disease risk in the general population, but that the cardiovascular risk associated with ABCA1 variants appears to be partly independent of measured HDL-C levels. This suggests ABCA1 affects vascular biology through mechanisms beyond simply lowering circulating HDL — including macrophage cholesterol efflux capacity, which is not fully captured by serum HDL-C measurements.

Practical Actions

Carriers of the G allele — particularly GG homozygotes — have somewhat lower expected HDL-C levels based on genetic predisposition. Two lifestyle factors have specific documented interactions with ABCA1 genotype. Nishida et al.⁶⁶ Nishida et al.
Nishida Y et al. The interaction between ABCA1 polymorphism and physical activity on HDL-cholesterol levels. J Lipid Res, 2020 found that the HDL-raising benefit of carrying a favorable ABCA1 allele was attenuated in physically inactive men — a gene-by-activity interaction suggesting that ABCA1-variant carriers who maintain aerobic fitness preserve more of their HDL-generating capacity. Dietary fat composition also matters: ABCA1 expression is regulated by liver X receptor (LXR), which is activated by oxysterols from cholesterol metabolism. Diets high in refined carbohydrates and trans fats suppress LXR-ABCA1 signaling, while unsaturated fats and plant sterols may modestly upregulate it.

Monitoring HDL-C at least annually is warranted for G allele carriers, as genetically low HDL may not trigger clinical concern on a single test but predicts sustained cardiovascular risk over time. Cholesterol efflux capacity — a measure of how effectively cells clear cholesterol — is not routinely measured but is the most direct readout of ABCA1 function; ask a cardiologist about functional lipid testing if standard panels are consistently borderline.

Interactions

rs2249891 sits at a locus that is in partial linkage disequilibrium with other ABCA1 variants, including rs1883025 (an extensively studied intronic variant with documented interactions with physical activity on HDL-C) and rs2575875 (an intronic enhancer variant with allele-specific regulatory activity in liver cells identified by Howard et al. 2019, PMID 31039173). Individuals carrying multiple ABCA1 variants with consistent directional effects on HDL regulation may have a compounded reduction in cholesterol efflux capacity compared to single-variant carriers.